BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 2033665)

  • 1. Rapid activation and subsequent down-regulation of the human immunodeficiency virus type 1 promoter in the presence of Tat: possible mechanisms contributing to latency.
    Drysdale CM; Pavlakis GN
    J Virol; 1991 Jun; 65(6):3044-51. PubMed ID: 2033665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1.
    Scala G; Quinto I; Ruocco MR; Mallardo M; Ambrosino C; Squitieri B; Tassone P; Venuta S
    J Virol; 1993 May; 67(5):2853-61. PubMed ID: 8386279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A sensitive promoter assay based on the transcriptional activator Tat of the HIV-1 virus.
    Koken SE; van Wamel J; Berkhout B
    Gene; 1994 Jul; 144(2):243-7. PubMed ID: 8039709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that a cell cycle regulator, E2F1, down-regulates transcriptional activity of the human immunodeficiency virus type 1 promoter.
    Kundu M; Srinivasan A; Pomerantz RJ; Khalili K
    J Virol; 1995 Nov; 69(11):6940-6. PubMed ID: 7474112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular factors regulate transactivation of human immunodeficiency virus type 1.
    Barry PA; Pratt-Lowe E; Unger RE; Luciw PA
    J Virol; 1991 Mar; 65(3):1392-9. PubMed ID: 1995949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the tat and nef gene products of human immunodeficiency virus type 1 (HIV-1) on transcription controlled by the HIV-1 long terminal repeat and on cell growth in macrophages.
    Murphy KM; Sweet MJ; Ross IL; Hume DA
    J Virol; 1993 Dec; 67(12):6956-64. PubMed ID: 8230418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to TAR hairpin element.
    Mayhood T; Kaushik N; Pandey PK; Kashanchi F; Deng L; Pandey VN
    Biochemistry; 2000 Sep; 39(38):11532-9. PubMed ID: 10995220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription.
    Bieniasz PD; Grdina TA; Bogerd HP; Cullen BR
    Proc Natl Acad Sci U S A; 1999 Jul; 96(14):7791-6. PubMed ID: 10393900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 Tat protein can transactivate a heterologous TATAA element independent of viral promoter sequences and the trans-activation response element.
    Roebuck KA; Rabbi MF; Kagnoff MF
    AIDS; 1997 Feb; 11(2):139-46. PubMed ID: 9030359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct transcriptional pathways of TAR-dependent and TAR-independent human immunodeficiency virus type-1 transactivation by Tat.
    Yang L; Morris GF; Lockyer JM; Lu M; Wang Z; Morris CB
    Virology; 1997 Aug; 235(1):48-64. PubMed ID: 9300036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence.
    Tiley LS; Madore SJ; Malim MH; Cullen BR
    Genes Dev; 1992 Nov; 6(11):2077-87. PubMed ID: 1427073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infection and replication of Tat- human immunodeficiency viruses: genetic analyses of LTR and tat mutations in primary and long-term human lymphoid cells.
    Chang LJ; Zhang C
    Virology; 1995 Aug; 211(1):157-69. PubMed ID: 7645208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdominant mutants of I kappa B alpha block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication.
    Beauparlant P; Kwon H; Clarke M; Lin R; Sonenberg N; Wainberg M; Hiscott J
    J Virol; 1996 Sep; 70(9):5777-85. PubMed ID: 8709193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transactivation of heterologous promoters by HIV-1 tat.
    Han P; Brown R; Barsoum J
    Nucleic Acids Res; 1991 Dec; 19(25):7225-9. PubMed ID: 1662814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repression in vitro, by human adenovirus E1A protein domains, of basal or Tat-activated transcription of the human immunodeficiency virus type 1 long terminal repeat.
    Song CZ; Loewenstein PM; Green M
    J Virol; 1995 May; 69(5):2907-11. PubMed ID: 7707515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185.
    Wu F; Garcia J; Sigman D; Gaynor R
    Genes Dev; 1991 Nov; 5(11):2128-40. PubMed ID: 1936997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reciprocal in vitro interactions between human herpesvirus-6 and HIV-1 Tat.
    Di Luca D; Secchiero P; Bovenzi P; Rotola A; Caputo A; Monini P; Cassai E
    AIDS; 1991 Sep; 5(9):1095-8. PubMed ID: 1657039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retroviral vector with a CMV-IE/HIV-TAR hybrid LTR gives high basal expression levels and is up-regulated by HIV-1 Tat.
    Robinson D; Elliott JF; Chang LJ
    Gene Ther; 1995 Jun; 2(4):269-78. PubMed ID: 7552987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions of thyroid hormone receptor with the human immunodeficiency virus type 1 (HIV-1) long terminal repeat and the HIV-1 Tat transactivator.
    Desai-Yajnik V; Hadzic E; Modlinger P; Malhotra S; Gechlik G; Samuels HH
    J Virol; 1995 Aug; 69(8):5103-12. PubMed ID: 7609079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The human immunodeficiency virus type 1 Tat antagonist, Ro 5-3335, predominantly inhibits transcription initiation from the viral promoter.
    Cupelli LA; Hsu MC
    J Virol; 1995 Apr; 69(4):2640-3. PubMed ID: 7884917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.